News Sentiment

NTRP sentiment intelligence

NextTrip Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Weighted score 47 Balanced news tone 31 relevant articles
Exchange NASDAQ United States
Sector Consumer Cyclical Market context
Industry Travel Services Read-through group
Latest close 2.11 Week of 10 Jul 2026
Weighted tone 47/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 31

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.7% over one week, -2.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

NextTrip, Inc. (NTRP) Reports Q1 Loss, Tops Revenue Estimates

Market Reaction

Balanced read

53/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction 0.7% Price digesting
Trend fit Trend inactive -2.5% over four weeks
Fair value -27.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 22
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 31
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
ACCESS Newswire 6
dars.gov.et 3
Market source 2
simplywall.st 2
marketscreener.com 1
Investing.com Canada 1
TradingKey 1

Event Lens

What the news is about

Classified themes
Market update 20
Earnings 4
Balance sheet 4
Deals and strategy 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-31 of 31
GlobeNewswire Direct company coverage

Safirstein Metcalf LLP Announces That A Class Action Lawsuit Has Been Filed Against Neurotrope, Inc. - NTRP

Safirstein Metcalf LLP has announced a class action lawsuit filed against Neurotrope, Inc. (NASDAQ:NTRP) for allegedly issuing materially false and misleading statements regarding the efficacy of its lead product candidate, Bryostatin-1. The lawsuit covers the period between Janu

Tone
Negative 17/100
Event
Regulatory and legal
Published
19 May 2017 17:30
Source
GlobeNewswire